Well Health: Consensus Price Target Climbs To $11.83 Following MyHealth Acquisition

WELL Health Technologies Corp. (TSX: WELL) this week announced that they would be acquiring MyHealth for total consideration of C$266.3 million. This is being completed via a combination of C$82 million in cash, $94.3 million in shares, a C$30 million convertible note, and a potential earn-out payment of up to C$60 million paid in cash. MyHealth was founded in 2013 and now has 48 stores across Ontario with over 760 physicians. WELL Health said that the company has a 5-year CAGR of 40% for revenue and EBITDA which includes a 15% organic growth rate.

The next day, the company announced that they have lenders committing to a C$140 million senior secured credit facility, with a C$60 million accordion feature. The credit facility has a floating rate but will decrease as MyHealths leverage decreases.

Many analysts have increased their 12-month price target off the back of this acquisition, the new weighted average sits at C$11.83, a 50% upside. The company has 12 analysts covering the name, with three of them having strong buy ratings and nine having buy rating. The street high sits at C$13.50 and the lowest is C$9.50.

In Haywood’s note on this acquisition, they reiterated their C$12.00 price target and buy rating. The firm stated that this merger looks accretive and reiterates that WELL Health is one of their top picks, commenting that the company is on a “stellar trajectory with rapid upward movements in the stock.”

Colin Healey, their analyst, says that this deal will bring $100 million in annual revenue, bringing Well to an almost $400 million revenue run rate. He also believes that the deal provides minimal dilution to current investors with roughly 5% dilution. Healey says that WELL Health will be paying 2.1x Pro-forma 2021 revenue or 10.3x Pro-forma 2021 EBITDA.

Below you can Haywood’s revised 2021 and 2022 estimates to incorporate the MyHealth acquisition as well as other pending acquisitions.

Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.